Trial Profile
Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination With MHC Class I Up-Regulation and the Anti-PD-L1 Antibody Avelumab
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Merkel cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 25 Feb 2022 Status changed from active, no longer recruiting to discontinued.
- 16 Nov 2018 Planned primary completion date changed from 15 Jul 2019 to 20 Jun 2022.
- 16 Nov 2018 Status changed from recruiting to active, no longer recruiting.